Peptide Therapeutics Market: R&D Consistency Drives Sector Growth
The global Peptide Therapeutics Market is projected to reach a valuation of US$ 47 Bn in 2025, with sales growing at a prolific CAGR of 11% from 2022 to 2025. Scaling up from an estimated value of US$ 34.4 Bn in 2022, the peptide therapeutics market is fuelled by the various benefits associated with the product. Peptide medicines have been used to treat metabolic illnesses for a very long time and will likely continue to do so over the forecasted period.
Owing to the benefits related to the consumption of peptide
therapeutics as well as the product’s wide range of applications in
pharmaceuticals and the biotechnology sector, the market outlook for peptide
therapeutics is highly positive in the upcoming years. Manufacturers of peptide
therapeutics have realized the vital role that the product can play in meeting
unfulfilled medical needs. Further, peptide therapeutics can be a preferred
alternative to small molecule and biological therapeutics. All of these factors
have led to an upsurge in research and investments in peptide drug recovery
over the last ten years and is expected to bode well for the future prospects
of the market.
Again, surging incidences of metabolic disorders and high
prevalence of cancer propel the demand for investments in research and
development activities in the field of peptide therapies. These illnesses are
the prime cause of death and disability all over the world. As a result, there
a greater demand for the development of peptide therapeutics. Peptide-based
drug delivery for cancer cells coupled with enhancements in the next generation
therapeutics will presumably supplement the market expansion of peptide
therapeutics. In addition to this, there’s a rise in the interest in therapeutic
peptide research due to commercial reasons. Thus, it is presumed that peptide
drug recovery will play a crucial role in the healthcare industry.
“Heightened application of peptides in the
treatment of diabetes and cancer will likely augment the sales of peptide
therapeutics in the global market over the forecast period,” says an FMI
analyst.
Key Takeaways:
- Popularity
of oral peptide-based drugs to generate attractive market opportunities.
- Peptide-based
therapeutics will continue to gain momentum in Cosmeceuticals.
- Government
support to aid market growth in North America.
- India
will offer various lucrative opportunities to the peptide therapeutics
industry.
- Based
on route of administration, parenteral route segment will continue to gain
preference during the assessment period.
Competitive Landscape
Eli Lilly and Company, AstraZeneca plc, Merck & Co.,
Inc., Ipsen S.A, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd.,
among others are some of the major players in the peptide therapeutics market
that are profiled in the full version of the report.
In a moderately competitive market, major players are
concentrating on market expansion activities. These organizations are engaging
in distribution agreements, white space exploration, and collaborative
ventures. The more established businesses are focusing on working with local
players in order to expand their production capacities and improve their
regional presence.
Read
More@ https://www.futuremarketinsights.com/reports/peptide-therapeutics-market
Comments
Post a Comment